Are we witnessing the start of a therapeutic revolution in acute myeloid leukemia?
- 17 January 2019
- journal article
- review article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 60 (6) , 1354-1369
Abstract
The 5-year overall survival rate of AML patients remains 25–40%. The prognosis is even more dismal for older patients who are ineligible for intensive chemotherapy and patients with secondary or relapsed/refractory AML. In 2017, 4 new drugs were approved by the US Food and Drug Administration for AML treatment: The FLT3 inhibitor midostaurin, the isocitrate dehydrogenase (IDH)-2 inhibitor enasidenib, a liposomal formulation of cytarabine and daunorubicin (CPX-351), and the anti-CD33 antibody gemtuzumab ozogamicin. Additionally, the IDH1 inhibitor ivosidenib has received FDA approval in July 2018. However, all these drugs were approved in certain settings and/or for certain subsets of AML patients. Herein, we review the mechanisms of actions and preclinical data, highlight pivotal clinical trial data, and discuss future directions and challenges for further development of these 5 novel therapeutics. Finally, we briefly overview some of the highly promising agents that are currently in advanced stages of clinical development.Keywords
This publication has 141 references indexed in Scilit:
- Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled TrialJournal of Clinical Oncology, 2013
- Targeting hedgehog in hematologic malignancyBlood, 2012
- Age-Related Prognostic Impact of Different Types of DNMT3A Mutations in Adults With Primary Cytogenetically Normal Acute Myeloid LeukemiaJournal of Clinical Oncology, 2012
- IDH mutation impairs histone demethylation and results in a block to cell differentiationNature, 2012
- A decade of exploring the cancer epigenome — biological and translational implicationsNature Reviews Cancer, 2011
- FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivoBlood, 2011
- Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromesBlood, 2008
- DNA Methylation Inhibitor 5-Aza-2′-Deoxycytidine Induces Reversible Genome-Wide DNA Damage That Is Distinctly Influenced by DNA Methyltransferases 1 and 3BMolecular and Cellular Biology, 2008
- Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrenceCancer, 2005
- Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantationBlood, 2003